A Multiple Oral Ascending Dose Study to Investigate the Safety, Pharmacokinetics and Catechol-O-methyltransferase (COMT) Inhibition Profiles of Opicapone in Healthy Male Subjects.
Phase of Trial: Phase I
Latest Information Update: 07 Jan 2016
At a glance
- Drugs Opicapone (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
- Sponsors Bial
- 25 Feb 2014 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health: NCT02071810).
- 11 Sep 2012 Results presented at the 16th Congress of the European Federation of Neurological Societies.